An open label, randomized study to evaluate the effects of seven monophasic oral contraceptive regimens on hemostatic variables: Outline of the protocol

Contraception

Volumn 59, Issue 6, 1999, Pages 345-355

  Winkler, U H ^a   Norris, L ^a   Gaspard, U ^a   Van Enk, A ^a   Mishell, D ^a   Voncken, D ^a   Klipping, C ^a  

^a Friedrich Ebert Krankenhaus   (Germany)

Author keywords

Ethinyl estradiol; Hemostasis; Oral contraceptives; Progestogen; Study design

Indexed keywords

BLOOD CLOTTING FACTOR 10A; C REACTIVE PROTEIN; DESOGESTREL; GESTODENE; LEVONORGESTREL; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; PROTEIN S;

ADULT; BLOOD CLOT LYSIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOSTASIS; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOEMBOLISM;

EID: 0032871051     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(99)00044-X     Document Type: Article

References (59)

1. Mammen E.F. Oral contraceptives and blood coagulation a critical review . Am J Obstet Gynecol. 142:1982;781-790.
2. Inman W.H.W., Vessey M.P., Westerholm B., Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee of Safety of Drugs. Br Med J. 2:1970;203-209.
3. Gerstman B.B., Piper J.M., Tomita D.K., Ferguson W.J., Stadel B.V., Lundin F.E. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol. 133:1991;32-37.
4. Vessey M.P., Mant D., Smith A., Yeates D. Oral contraceptives and venous thromboembolism findings from a prospective study . Br Med J. 292:1986;526.
5. Böttiger L.E., Boman G., Eklund G., Westerholm B. Oral contraceptives and thromboembolic disease effects of lowering oestrogen content . Lancet. 1:1980;1097-1101.
6. Bonnar J. Coagulation effects of oral contraception. Am J Obstet Gynecol. 157:1987;1042-1048.
7. Winkler U.H., Hölscher T., Schulte H., Zierleyn J.P., Collet W., Schindler A.E. Ethinylestradiol 20 versus 30 micrograms combined with 150 micrograms desogestrel a large comparative study of the effects of two low-dose oral contraceptives on the haemostatic system . Gynecol Endocrinol. 10:1996;265-271.
8. Jick H., Jick S.S., Gurewich V., Myers M.W., Vasilakis C. Risk of idiopathic cardiovascular death and non-fatal thromboembolism in women using oral contraceptives with differing progestogen components. Lancet. 346:1995;1589-1593.
9. Spitzer W.O., Lewis M.A., Heinemann L.A.J., Thorogood M., MacRae K.D. Third generation oral contraceptives and risk of venous thromboembolic disorders an international case-control study . Br Med J. 312:1996;83-88.
10. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestogens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet. 346:1995;1582-1588.
11. Bloemenkamp K.W.M., Rosendaal F.R., Helmerhorst F.M., Buller H.R., Vandenbroucke J.P. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third generation progestagen. Lancet. 346:1995;1593-1596.
12. Ball M.J., Ashwell E., Jackson M., Gillmer M.D. Comparison of two triphasic contraceptives with different progestogens effects on metabolism and coagulation proteins . Contraception. 41:1990;363-376.
13. Bonnar J., Daly L., Carroll E. Blood coagulation with a combination pill containing gestodene and ethinyl estradiol. Int J Fertil. 32:(suppl):1987;21-28.
14. Cohen H., Mackie I.J., Walshe K., Gillmer M.D., Machin S.J. A comparison of the effects of two triphasic oral contraceptives on haemostasis. Br J Haematol. 69:1988;259-263.
15. Gramolini R., Perrone G., Calzolari E., Mancone M., Maasci A., Materazzi P. Evaluation of some coagulation tests in women using low-dose oral contraceptives. Pat Clin Ost Gin. 15:1987;307-312.
16. Kjær A., Lebech A.M., Borggaard B., et al. Lipid metabolism and coagulation of two contraceptives correlation to serum concentrations of levonorgestrel and gestodene . Contraception. 40:1989;665-673.
17. Kloosterboer H.J., van Waijen R.G.A., van den Ende A. Effects of three low-dose oral contraceptive combinations on sex hormone binding globulin, corticosteroid binding globulin and antithrombin III activity in healthy women two monophasic desogestrel combinations (containing 0.020 or 0.030 mg ethinyl estradiol) and one triphasic levonorgestrel combination . Acta Obstet Gynecol Scand. 144:(suppl):1987;41-44.
18. Machin S.J., Mackie I.J., Walshe K., Gillmer M.D. Hemostatic changes induced by two low dose triphasic oral contraceptives. Thromb Haemost. 58:1987;279.
19. Melis G.B., Fruzzetti F., Nicoletti I., et al. A comparative study on the effects of a monophasic pill containing desogestrel plus 20 μg ethinylestradiol, a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulatory factors. Contraception. 43:1991;23-31.
20. Omsjö I.H., Oian P., Maltau J.M., Osterund B. Effects of two triphasic oral contraceptives containing ethinylestradiol plus levonorgestrel or gestodene on blood coagulation and fibrinolysis. Acta Obstet Gynecol Scand. 68:1989;27-30.
21. Prasad R.N.V., Koh S., Ratnam S.S. Effects of three types of combined OC pills on blood coagulation, fibrinolysis and platelet function. Contraception. 39:1989;369-384.
22. Rabe T., Runnebaum B., Kohlmeier M., Harenberg J., Weicker H. Clinical and metabolic effects of gestodene and levonorgestrel. Int J Fertil. 32:(suppl):1987;29-44.
23. Rákoczi I., Gero G., Demeter J., Gáti I. Comparative metabolic effects of oral contraceptive preparations containing different progestagens; effects of desogestrel + ethinylestradiol on the haemostatic balance. Arzneimittelforschung. 35:1985;630-633.
24. Refn H., Kjær A., Lebech A.M., Borggaard B., Schierup L., Bremmelgaard A. Metabolic changes during treatment with two different progestogens. Am J Obstet Gynecol. 163:1990;374-377.
25. Sirtori C.R., Calabresi L., Franceschini G., et al. Comparison of the lipoprotein and hemostatic changes after a triphasic and a monophasic low dose oral contraceptive in premenopausal middle-aged women. Atherosclerosis. 84:1990;203-211.
26. Vekemans M., Grippa J., Capel P., Fondu P. The effect of two low-dose contraceptives containing ethinylestradiol and desogestrel or D-norgestrel on blood clotting factors. Curr Ther Res. 42:1987;1109-1118.
27. Zichella L., Antonini R., Calzolari E., et al. Metabolic evaluation of women using three different oral contraceptives a comparison . Volpe A.R., Facchinetti F. Gynecological Endocrinology. 1987;399-403 Parthenon, Carnforth.
28. Quehenberger P., Loner U., Kaplotis S., et al. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. Thromb Haemost. 76:1996;729-734.
29. Koster T., Rosendaal F.R., Reitsma P.H., van der Velden P.A., Briët E., Vandenbroucke J.P. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms - The Leiden Thrombophilia Study (LETS). Thromb Haemost. 71:1994;719-722.
30. Janssen M.C.H., Verbruggen B.W., Hark P.J.Ct., Nováková I.R.O. Factor VIIa determination compared with D-dimer in diagnosis of deep venous thrombosis. Thromb Res. 86:1997;423-426.
31. Lidegaard O., Edström B., Kreiner S. Oral contraceptives and venous thromboembolism. A case-control study. Contraception. 57:1998;291-301.
32. Farmer R.D.T., Lawrenson R.A., Thomson C.R., Kennedy J.G., Hambleton I.R. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet. 349:1997;83-88.
33. Farmer R.D.T., Todd J.C., Lewis M.A., MacRae K.D., Williams T.J. The risk of venous thromboembolic disease among German women using oral contraceptives a database study . Contraception. 57:1998;67-70.
34. Suissa S., Blais L., Spitzer W.O., Cusson J., Lewis M.A., Heinemann L.A.J. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception. 56:1997;141-146.
35. Lewis M.A., Heinemann L.A.J., MacRae K.D., Bruppacher R., Spitzer W.O. The increased risk of venous thromboembolism and the use of third generation progestogens role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women . Contraception. 54:1996;5-13.
36. Jespersen J., Bertina R.M., Haverkate F. ECAT Assay Procedures A Manual of Laboratory Techniques: European Concerted Action on Thrombosis and Disabilities of the Commission of the European Communities . 1992;1-230 Kluwer, Dordrecht.
37. Jespersen J., Bertina R.M., Haverkate F. Laboratory Techniques in Thrombosis - a Manual. Second Revised Edition of ECAT Assay Procedures. 1999;1-308 Kluwer Academic Publishers, Dordrecht.
38. Jespersen J., Sidelmann J. A study of the conditions and accuracy of the thrombin time assay of plasma fibrinogen. Acta Haematol. 67:1982;2-7.
39. Bladbjerg E.M., Marckmann P., Sandstrom B., Jespersen J. Non-fasting factor VII coagulant activity (FVII:C) increased by high-fat diet. Thromb Haemost. 71:1994;755-758.
40. Rosen S., Johansson K., Lindberg K., Dahlbäck B. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasma from healthy individuals. The APC Resistance Study Group. Thromb Haemost. 72:1994;255-260.
41. Gram J., Jespersen J. A functional plasminogen assay utilizing the potentiating effect of fibrinogen to correct for the overestimation of plasminogen in pathological plasma samples. Thromb Haemost. 53:1985;255-259.
42. Ranby M., Bergsdorf N., Nilsson T., Mellbring G., Winblad B., Bucht G. Age dependence of tissue type plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent assay. Clin Chem. 32:1986;2160-2165.
43. Declerk P.J., Moreau H., Jespersen J., Gram J., Kluft C. Multicentre evaluation of commercially available methods for the immunological determination of plasminogen activator inhibitor-1 (PAI-1). Thromb Haemost. 70:1993;858-863.
44. Westgard J.O., Groth T., Aronsson T., de Verdier C. Combined shewhart-cusum control chart for improved quality control in clinical chemistry. Clin Chem. 23:1977;1881-1887.
45. Winkler U.H. Blood coagulation and oral contraceptives. A critical review. Contraception. 57:1998;203-209.
46. Bauer K.A., Rosenberg R.D. The pathophysiology of the prethrombotic state in humans insights gained from studies using markers of hemostatic system activation . Blood. 70:1987;343-350.
47. Kluft C., Lansink M. Effects of oral contraceptives on hemostasis variables. Thromb Haemost. 78:1997;315-326.
48. Winkler U.H., Howie H., Bühler K., Korver T., Geurts T.B.P., Bennink H.J.T. A randomized controlled double-blind study of the effects on hemostasis of two progestogen-only pills containing 75 μg desogestrel or 30 μg levonorgestrel. Contraception. 57:1998;385-392.
49. van der Meer F.J.M., Koster T., Vandenbroucke J.P., Briët E., Rosendaal F.R. The Leiden thrombophilia study (LETS). Thromb Haemost. 78:1997;631-635.
50. Petersen K.R., Sidelmann J., Skouby S.O., Jespersen J. Effects of monophasic low-dose oral contraceptives on fibrin formation and resolution in young women. Am J Obstet Gynecol. 168:1993;32-38.
51. Weinges K.F., Wenzel E., Hellstern P., Geurts T.B.P., Dieben T.O.M. The effects of two phasic oral contraceptives on hemostasis and platelet function. Adv Contracept. 11:1995;227-237.
52. Carvalho de Sousa J., Bruckert E., Giral P., et al. Coagulation factor VII and plasma triglycerides. Haemostasis. 19:1989;125-130.
53. Cardiovascular Disease and Steroid Hormone Contraception. 1998;World Health Organization, Geneva.
54. Jespersen J. Pathophysiology and clinical aspects of fibrinolysis and inhibition of coagulation. Experimental and clinical studies with special reference to women on oral contraceptives and selected groups of thrombosis prone patients. Dan Med Bull. 35:1988;1-33.
55. Jespersen J. Plasma resistance to activated protein C an important link between venous thromboembolism and combined oral contraceptives - a short review . Eur J Contracept Reprod Health Care. 1:1996;3-11.
56. Rosing J., Tans G., Nicolaes G.A.F., et al. Oral contraceptives and venous thrombosis different sensitivities to activated protein C in women using second- and third-generation oral contraceptives . Br J Haematol. 97:1997;233-238.
57. Heinemann L.A.J., Assmann A., Spannagl M., et al. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism. Contraception. 58:1998;321-322.
58. Schramm W., Heinemann L.A.J. Oral contraceptives and venous thromboembolism acquired APC resistance? Br J Haematol. 98:1997;491-492.
59. Prins M.H., Hirsh J. A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism. Arch Intern Med. 151:1991;1721-1731.